Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.
The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
The FDA decision was based on results from three late-stage clinical studies, including two Phase 3 trials conducted in ...
The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...
MedPage Today on MSN
FDA Greenlights First Motion Sickness Drug in More Than 40 Years
The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback